Albireo Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for ALBIREO, and when can generic versions of ALBIREO drugs launch?
ALBIREO has one approved drug.
There are eight US patents protecting ALBIREO drugs.
There are one hundred and nineteen patent family members on ALBIREO drugs in forty-six countries and eight supplementary protection certificates in eight countries.
Summary for Albireo
| International Patents: | 119 |
| US Patents: | 8 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Albireo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Albireo | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | RX | Yes | No | 10,981,952 | See Plans and Pricing | See Plans and Pricing | ||||
| Albireo | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | RX | Yes | Yes | 10,975,046 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Albireo | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | RX | Yes | No | 9,694,018 | See Plans and Pricing | See Plans and Pricing | ||||
| Albireo | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
| Albireo | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | RX | Yes | Yes | 10,981,952 | See Plans and Pricing | See Plans and Pricing | ||||
| Albireo | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | RX | Yes | Yes | 10,975,046 | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Albireo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Albireo | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | 7,132,416 | See Plans and Pricing |
| Albireo | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | 7,132,416 | See Plans and Pricing |
| Albireo | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | 7,132,416 | See Plans and Pricing |
| Albireo | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | 7,132,416 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Albireo Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 1582151 | See Plans and Pricing |
| Hong Kong | 1188730 | See Plans and Pricing |
| Jordan | P20200299 | See Plans and Pricing |
| Israel | 279468 | See Plans and Pricing |
| Serbia | 57778 | See Plans and Pricing |
| Malaysia | 163275 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Albireo Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3400944 | 122021000075 | Germany | See Plans and Pricing | PRODUCT NAME: ODEVIXIBAT, EINSCHLIESSLICH PHARMAZEUTISCH VERTRAEGLICHER SALZE UND SOLVATE DAVON, INSBESONDERE ODEVIXIBAT-HYDRAT; REGISTRATION NO/DATE: EU/1/21/1566 20210716 |
| 3400944 | LUC00242 | Luxembourg | See Plans and Pricing | PRODUCT NAME: ODEVIXIBAT ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BYLVAY); AUTHORISATION NUMBER AND DATE: EU/1/21/1566 20210719 |
| 3400944 | CA 2022 00001 | Denmark | See Plans and Pricing | PRODUCT NAME: ODEVIXIBAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1566 20210719 |
| 3400944 | 48/2021 | Austria | See Plans and Pricing | PRODUCT NAME: ODEVIXIBAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1566 (MITTEILUNG) 20210719 |
| 3400944 | PA2021012 | Lithuania | See Plans and Pricing | PRODUCT NAME: ODEVIKSIBATAS ; REGISTRATION NO/DATE: EU/1/21/1566 20210716 |
| 3400944 | 301157 | Netherlands | See Plans and Pricing | PRODUCT NAME: ODEVIXIBAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1566 20210719 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
